| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Investment in short-term investment | 25 | - |
| Acquisition and development of intangible assets | 411 | 114 |
| Net cash from (used) in investing activities | 206 | 580 |
| Repayment of a long-term loan | - | -1 |
| Net proceeds from the issuance of common stock | 3,963 | 852 |
| Repayment of long-term loan | 2 | - |
| Net cash provided by financing activities | 3,961 | 851 |
| Effects of exchange rate changes on cash and cash equivalents | 30 | 25 |
| Net increase in cash and cash equivalents | 700 | 49 |
| Cash and cash equivalents at beginning of period | 405 | - |
| Cash and cash equivalents at end of period | 1,105 | - |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)